Neurologia最新文献

{"title":"ADAM10 and its role in Alzheimer disease.","authors":"Pablo Agüero, Estrella Gómez Tortosa","doi":"10.1016/j.nrleng.2026.502083","DOIUrl":"https://doi.org/10.1016/j.nrleng.2026.502083","url":null,"abstract":"<p><strong>Background: </strong>The amyloidogenic pathway of amyloid precursor protein (APP) processing is well known in the pathogenesis and therapeutics of Alzheimer disease (AD), whereas the non-amyloidogenic pathway has been less studied. ADAM10 is the main α-secretase responsible for this pathway in the human brain.</p><p><strong>Content: </strong>ADAM10 belongs to a family of transmembrane proteins with catalytic activity. It acts as an α-secretase on APP and many other substrates, some of which are particularly relevant in the central nervous system. The ADAM10 gene has been identified in genome-wide association studies of patients with AD; mutations have been reported in families with strong functional support but incomplete segregation; and haploinsufficiency has been reported in a family carrying a nonsense mutation. However, genetic studies of AD cohorts have not identified causal variants. ADAM10 levels in biological fluids show conflicting results, except in platelets, where patients with AD consistently exhibit reduced levels. Stimulation of ADAM10 as a therapeutic target offers new opportunities through various components and such measures as physical exercise. However, only one (positive) clinical trial has been published to date, using the retinoid acitretin.</p><p><strong>Conclusions: </strong>ADAM10 plays a fundamental role in brain function, and sufficient studies support its involvement in AD pathogenesis. There are only isolated examples of ADAM10 mutations as a genetic cause, but these encourage continued screening in familial AD. ADAM10 levels in platelets could be considered as a biomarker. The enhancement of ADAM10 expression in AD remains a therapeutic target that requires further research.</p>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":" ","pages":"502083"},"PeriodicalIF":0.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to access to anti-CGRP monoclonal antibodies in Spain: survey of neurologists, hospital pharmacists, and patients.","authors":"Pablo Irimia, Pilar Díaz Ruiz, Isabel Colomina, Roberto Belvís, José Miguel Lainez","doi":"10.1016/j.nrleng.2026.502081","DOIUrl":"https://doi.org/10.1016/j.nrleng.2026.502081","url":null,"abstract":"<p><strong>Introduction: </strong>Neurologists, hospital pharmacists (HP), and patients advocate for improved access to anti-CGRP monoclonal antibodies (mAbs) in migraine prophylaxis.</p><p><strong>Objectives: </strong>To identify the barriers to access to anti-CGRP mAbs in Spain and to propose potential solutions.</p><p><strong>Material and methods: </strong>Cross-sectional study with online surveys aimed at neurologists, HPs, and patients. Descriptive statistics were used to analyse the data. Categorical variables were expressed in terms of frequency and percentage.</p><p><strong>Results: </strong>A total of 55.1% of neurologists and 67.4% of HPs reported that at their hospitals, the criteria of the therapeutic positioning statement (TPS)were followed on a case-by-case basis to authorise the dispensing of anti-CGRP mAbs. However, more than 30% of neurologists and HPs reported that they had their own protocols. A total of 62.8% of neurologists and 23.3% of HPs disagreed with some TPS criteria and, according to 41.9% of pharmacists, not all neurologists at their hospital were able to prescribe anti-CGRP mAbs. Neurologists and HPs considered that the TPS criteria should be reviewed periodically. Some 32.9% of patients considered access to a migraine specialist to have been difficult. A total of 88.4% of neurologists and 81.4% of HPs thought that referral from primary care to a specialised consultation should be faster.</p><p><strong>Conclusions: </strong>The main barriers to accessing anti-CGRP mAbs are the difficulty of accessing a neurology specialist, and the strict TPS criteria and differences in their application between autonomous communities and hospitals. Neurology referral systems should be improved and TPS criteria reviewed.</p>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":" ","pages":"502081"},"PeriodicalIF":0.0,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of insomnia in the neurology consultation of a multidisciplinary sleep unit.","authors":"María José Abenza Abildúa, Eugenio Suárez Gisbert, Francisco José Navacerrada Barrero, Vanesa Lores Gutiérrez, Débora Rojano Baz, África Díaz Pérez, Álvaro Gómez de la Riva, Ambrosio Miralles Martínez","doi":"10.1016/j.nrleng.2026.502082","DOIUrl":"https://doi.org/10.1016/j.nrleng.2026.502082","url":null,"abstract":"<p><strong>Introduction: </strong>This study analyses the most common types of insomnia and comorbidities in patients referred to our sleep unit's neurology consultation, and how these patients are managed.</p><p><strong>Material and methods: </strong>We conducted a retrospective, observational, descriptive study of consecutive patients diagnosed with insomnia at our hospital's sleep unit between January and December 2023, inclusive.</p><p><strong>Results: </strong>Of the 200 patients registered in 2023, 127 (63.5%) were diagnosed with insomnia. Of these, 64 were women (50.39%) and 63 were men (49.60%), with a mean age of 53.24 years (SD: 15.372). In our sample, the main aetiology or associated comorbidity of insomnia according to the American Academy of Sleep Medicine classification (insomnia associated with mental illness, medical illness, and other sleep disorders) was as follows: 77 patients (60.62%) with active mental disorder at the time of the consultation (anxiety, dysthymia, depression, hyperalertness/stress/rumination) and 30 patients with insomnia associated with a medical illness. The following sleep comorbidities were observed: periodic leg movements (n = 9), restless legs syndrome (n = 15), and obstructive sleep apnoea (n = 45). Of the 31 patients with insomnia associated with medical disorders, 16 also presented reactive anxiety/depression that contributed to the persistence or worsening of insomnia. Of the total 127 patients, 77 patients had insomnia associated with a mental condition, and 16 had insomnia secondary to both medical and mental conditions (73.22%).</p><p><strong>Conclusions: </strong>Insomnia associated with mental conditions (depression, anxiety, dysthymia) is the most common type of insomnia. Its prevalence has increased since the COVID-19 pandemic, and now accounts for two-thirds of the patients assessed at the neurology consultations of sleep units. Idiopathic insomnia accounts for barely one-tenth of cases. Patients with chronic insomnia would benefit from initial assessment by mental health professionals, who are able to diagnose the most prevalent comorbidities and triggers, as well as other disorders that are frequently overlooked by other professionals. This approach would also improve the identification of patients eligible for cognitive-behavioral therapy, the first line of treatment for insomnia according to clinical guidelines, ultimately improving patient care and healthcare resource management.</p>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":" ","pages":"502082"},"PeriodicalIF":0.0,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of personality traits in response to anti-CGRP monoclonal antibodies in patients with refractory migraine.","authors":"I Ros González, M M López Navarro, A Recio García, Y González Osorio, D García Azorín, Á L Guerrero Peral","doi":"10.1016/j.nrleng.2026.502085","DOIUrl":"https://doi.org/10.1016/j.nrleng.2026.502085","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study is to determine whether certain personality traits may predict response to anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAb) in patients with migraine.</p><p><strong>Methods: </strong>We conducted an observational, prospective study of a cohort of patients with chronic migraine (CM) or high-frequency episodic migraine (HFEM) treated with anti-CGRP mAbs according to Spanish national healthcare system reimbursement criteria at the headache unit of a tertiary hospital. We gathered clinical and demographic data. Treatment response was defined as a ≥ 50% decrease in the number of headache days per month at 3 months of treatment. The Salamanca Screening Test was used to evaluate personality traits.</p><p><strong>Results: </strong>We included 104 patients, 88 of whom were women (84.6%), with a mean age (standard deviation) of 46.5 years (10.3) at treatment onset. A total of 88 patients (84.6%) had a diagnosis of CM. Fifty-two patients received galcanezumab and the remaining 52 were treated with fremanezumab. Response was achieved in 75 patients (72.1%). Compared to non-responders, responders presented a younger age at treatment onset (44.1 [10.6] vs 49.7 [9.1]; P =  .006), shorter latency from migraine onset to treatment onset (22.4 [12.2] vs 28.2 [14.4] years; P =  .029), and shorter latency from CM or HFEM diagnosis to treatment onset (90.4 [51.9] vs 118.5 [61.2] months; P =  .013). The most prevalent personality traits in our sample were histrionic (64.4%), anankastic (52.9%), and anxious (50%). Borderline personality was found to predict lack of response to treatment (OR = 0.24 [0.09-0.64]).</p><p><strong>Conclusions: </strong>Personality traits, along with other clinical and demographic variables, may predict response to treatment with anti-CGRP mAbs in patients with migraine.</p>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":" ","pages":"502085"},"PeriodicalIF":0.0,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Normative data for the Reading the Mind in the Eyes Test in a Spanish adult population.","authors":"Carmen Pérez-Enríquez, Greta García-Escobar, María Paz Fernández-Lozano, Rosa María Manero, Jordi Peña-Casanova, Gonzalo Sánchez-Benavides","doi":"10.1016/j.nrleng.2026.502080","DOIUrl":"https://doi.org/10.1016/j.nrleng.2026.502080","url":null,"abstract":"<p><strong>Objective: </strong>The present study aims to provide Spanish normative data for the Reading the Mind in the Eyes Test (RMET) in a Spanish adult population.</p><p><strong>Method: </strong>The normative sample consisted of 167 subjects aged between 20 and 94 years. The main sociodemographic variables (age, education level, and sex) were analysed, and raw scores were transformed into age-adjusted scaled scores, with the corresponding adjustments when a significant influence was found.</p><p><strong>Results: </strong>Age had a negative effect on test performance in the oldest age group (≥ 50 years), whereas education level had a positive effect on test performance in both age groups; furthermore, women performed better than men. Education level (r² = 0.226 in the < 50 years group; r² = 0.237 in the ≥ 50 years group) and sex (r² = 0.260 in the < 50 years group; r² = 0.287 in the ≥ 50 years group) had a greater influence on test performance than age (r² = 0.000 in the < 50 years group; r² = 0.084 in the ≥ 50 years group).</p><p><strong>Conclusion: </strong>The normative data provided may be useful to improve the representativeness of RMET performance in young and older adults from the Spanish population.</p>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":" ","pages":"502080"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147825162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Descriptive analysis of mortality due to Parkinson's disease and Alzheimer disease in Argentina.","authors":"Florencia Molinatti, Laura De Gracia, Alejandro Oliva","doi":"10.1016/j.nrleng.2026.502084","DOIUrl":"https://doi.org/10.1016/j.nrleng.2026.502084","url":null,"abstract":"<p><strong>Introduction: </strong>Parkinson's disease (PD) and Alzheimer disease (AD), along with other nervous system disorders, are the leading causes of global disease burden. Although global trends have remained stable in recent decades, an increase in years of life lost due to these diseases has been recorded. In Argentina, though no prevalence records are available for PD and AD, reliable mortality data do exist. Similarities and differences in mortality caused by PD and AD are analysed in the present study.</p><p><strong>Methods: </strong>The study was performed in the total population between 2000 and 2019. Age-standardised mortality rates (ASMR) were calculated. At the national level, annual trends were analysed and comparisons between provinces were made. Subsequently, spatial autocorrelation in the Centre Region (CR) was examined.</p><p><strong>Results: </strong>Between 2000 and 2019, there were no statistically significant changes in ASMR for PD or AD, in either sex. In most cases, ASMR in the CR and its provinces were higher than the national average. At the department level, a trend towards the concentration of similar values was observed, with the exception of mortality due to PD among women.</p><p><strong>Conclusions: </strong>The CR exhibits a higher ASMR than the national average, with rates of mortality due to AD in men in Santa Fe province being particularly noteworthy. It also shows a distinct spatial concentration pattern, with 2 distinct clusters. Further research is required to investigate the underlying sociodemographic and environmental factors contributing to this pattern.</p>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":" ","pages":"502084"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147825189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining therapeutics in vATTR: Evaluation of response predictors to tafamidis and patisiran treatment in a non-endemic area. A proposal for a novel individualised therapeutic approach","authors":"L. Martínez-Vicente ,&nbsp;V. Gajate-García ,&nbsp;G. Gutiérrez-Gutiérrez ,&nbsp;Á.L. Guerrero-Peral ,&nbsp;A. Horga ,&nbsp;A. Guerrero-Sola ,&nbsp;J. Álvarez-Troncoso ,&nbsp;M.A. Restrepo-Córdoba ,&nbsp;J. Goirigolzarri-Artaza ,&nbsp;S. Martín-Albarrán ,&nbsp;A. Valverde-Megías ,&nbsp;E. González-López ,&nbsp;P. García-Pavía ,&nbsp;J. Matías-Guiu ,&nbsp;L. Galán-Dávila","doi":"10.1016/j.nrleng.2026.501920","DOIUrl":"10.1016/j.nrleng.2026.501920","url":null,"abstract":"<div><h3>Introduction</h3><div>Hereditary transthyretin amyloidosis (vATTR) is a progressive genetic disorder with several approved treatments. We investigated treatment responses to tafamidis and patisiran in vATTR patients to identify predictive response factors.</div></div><div><h3>Methods</h3><div>Retrospective analysis on vATTR patients treated with tafamidis or patisiran from October 2012 to September 2022. Treatment responses were assessed as “good,” “partial,” or “non-response.” We analysed pre-treatment clinical and laboratory data to identify predictors of treatment response.</div></div><div><h3>Results</h3><div>Of the 53 patients, 44 received tafamidis and 23 received patisiran; 14 were treated with both drugs sequentially. Predictors of good response to tafamidis were shorter diagnostic delay (≤1 year), less severe neurological impairment (Coutinho stage 1, Neuropathy Impairment Score [NIS]<!--> <!-->≤<!--> <!-->7), and better sudomotor function in the feet (≥50<!--> <!-->μS) before treatment. Factors associated with non-response were greater disability (baseline Polyneuropathy Disability score<!--> <!-->=<!--> <!-->2), large fibre involvement, and significant weight loss. Predictors of a good response to patisiran included lower pre-treatment disease severity (Coutinho stage 1, NIS<!--> <!-->≤<!--> <!-->40). We propose an individualised therapeutic approach using predictive factors to guide initial treatment.</div></div><div><h3>Conclusions</h3><div>This study identifies predictive factors for response to tafamidis and patisiran in vATTR patients, highlighting baseline NIS as a critical predictor. We propose a novel therapeutic algorithm for personalised treatment strategies with potential to avoid years of ineffective treatment.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 3","pages":"Article 501920"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147631605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurological primary care: assessment of teleconsultation as the only access gateway to neurological care from primary care","authors":"S. Pérez-Sánchez ,&nbsp;M.Á. Quesada García ,&nbsp;F. Sánchez Fernández ,&nbsp;P.L. Guardado Santervás ,&nbsp;J. Dotor ,&nbsp;E. Martínez Fernández ,&nbsp;M. Villagran García ,&nbsp;M. Ben Yelun ,&nbsp;J.D. Guerra Hiraldo ,&nbsp;M.Á. Acevedo ,&nbsp;J.M. Herrerías ,&nbsp;J. Moreno Conde ,&nbsp;Á. Rodríguez ,&nbsp;I. Muñoz Martínez ,&nbsp;J. Montaner","doi":"10.1016/j.nrleng.2026.501919","DOIUrl":"10.1016/j.nrleng.2026.501919","url":null,"abstract":"<div><h3>Introduction</h3><div>The demand for neurological care from primary care (PC) has grown in recent years. Teleconsultation is being consolidated as another tool in the management of this demand. Therefore, we analyse the teleconsultation activity carried out in our region after its implementation as the only gateway to neurological care.</div></div><div><h3>Method</h3><div>Teleconsultation from PC was implemented in the 2 healthcare districts of our region in 2020, with a mixed referral system (in-person and teleconsultation). In March 2023, it was implemented as the only gateway to the neurology department in one of the healthcare districts (the rural area, Sevilla Norte), with the mixed system remaining in place for the other. Data were collected on its use during the 6 months after implementation (total number, average delay, case-resolution capacity [discharge, follow-up, consultation]). A comparison was made with the same period of the previous year.</div></div><div><h3>Results</h3><div>A total of 7377 teleconsultations have been registered since the implementation of the system, with a year-on-year increase (1247 in 2020, 2370 in 2021, 2542 in 2022, and 3008 until August 2023). This is reflected in the increased access to the neurology department from primary care between both periods. The mean waiting time for in-person referral decreased (41.92 [15.96] days in 2022 vs 12.66 [11.34] days in 2023; <em>P</em> &lt; .001) and the number of appointments scheduled outside the legally established timeframe (&gt; 60 days) fell by 96.7% (1936 patients [44.2%] in 2022 and 64 patients [1.2%] in 2023). Teleconsultation also improved access, with a 68.09% decrease in the mean delay (35 [27.17] hours in 2022 vs 11.17 [4.12] hours in 2023; <em>P</em> = .060). In terms of teleconsultation case-resolution capacity, the number of discharges from teleconsultation remained above 50% (59.45 [8.93%] in 2022 and 54.07 [6.02%] in 2023, <em>P</em> = .249).</div></div><div><h3>Conclusions</h3><div>TC as a single gateway is useful and efficient in managing demand from PC. It improves access to the population, with patients being attended within hours of consultation, and allows more than half of consultations to be resolved, avoiding unnecessary consultations and travel to the hospital.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 3","pages":"Article 501919"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147328859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus document of the Spanish Society of Neurology on the prevention of cognitive decline and dementia","authors":"M.J. Gil Moreno ,&nbsp;C. Terrón Cuadrado ,&nbsp;M.S. Manzano Palomo ,&nbsp;A. Delgado Alvarez ,&nbsp;M. Eimil Ortiz ,&nbsp;G. Garcia Ribas ,&nbsp;M. Llanero Luque ,&nbsp;A. Marcos Dolado ,&nbsp;J. Matias-Guiu Antem ,&nbsp;C. Ochoa Lopez ,&nbsp;N. Rodriguez Espinosa ,&nbsp;M. Salas Carrillo ,&nbsp;A. Vieira Campos","doi":"10.1016/j.nrleng.2026.501918","DOIUrl":"10.1016/j.nrleng.2026.501918","url":null,"abstract":"<div><div>Recent studies have demonstrated a relationship between the development of cognitive impairment and dementia and lifestyle-related risk factors, many of which are potentially modifiable, making it possible to prevent dementia through a public health approach that includes the implementation of key interventions to delay or slow cognitive decline or dementia.</div><div>This consensus statement was prepared by a group of experts in cognitive pathology and the Neurogeriatrics Study Group of the Spanish Society of Neurology.</div><div>This document consists of a review of the existing literature, and its main objective is to serve as a guide for healthcare professionals interested in cognitive impairment and dementia. The different modifiable risk factors related to cognitive decline and dementia are listed and related aspects are analysed; it also presents a series of basic recommendations.</div><div>This document has been drafted to be a useful tool in the clinical practice of professionals providing care to patients with cognitive impairment and dementia.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 3","pages":"Article 501918"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147328863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond indomethacin: a case report of chronic paroxysmal hemicrania with remarkable response to non-invasive vagus nerve stimulation","authors":"A. Jaimes,&nbsp;A. Gómez,&nbsp;O. Pajares,&nbsp;J. Rodríguez-Vico","doi":"10.1016/j.nrleng.2026.501917","DOIUrl":"10.1016/j.nrleng.2026.501917","url":null,"abstract":"","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 3","pages":"Article 501917"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147328861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}